R&D channel feed

Sanofi hints at 'class ef­fec­t' for mR­NA flu shot as it un­veils vac­cine R&D plans dri­ven by $3.2B deal

Last year
Pharma

In a first, FDA signs off on Cell­Tran­s' type 1 di­a­betes cell ther­a­py days af­ter in­dus­try's eyes fix­at­ed on Ver­tex da­ta

Last year
Cell/Gene Tx
FDA+

FDA ad­comm votes in fa­vor of Ipsen's fi­brodys­pla­sia drug

Last year
Pharma

Q&A with Tran­sCel­er­ate’s new CEO Jan­ice Chang: Bring­ing the tri­al in­fra­struc­ture to pa­tients

Last year
FDA+

A cen­tu­ry af­ter the last ma­jor TB vac­cine break­through, Gates and Well­come com­mit $550M for PhI­II test of GSK shot

Last year

Meet ‘Fan­zor,’ a cousin of CRISPR and Feng Zhang’s new gene edit­ing tool

Last year
Discovery

With just one re­sponse in 47 pa­tients, Foghorn stops work on lead can­di­date in ad­vanced eye can­cer

Last year

Eton hand­ed sec­ond CRL for methanol poi­son­ing treat­ment

Last year
FDA+

Fresh off ap­proval, Ab­b­Vie and Gen­mab's CD3xCD20 bis­pe­cif­ic Ep­kin­ly scores in an­oth­er type of blood can­cer

Last year

Cor­rect­ed: Bay­er's Blue­Rock group moves Parkin­son's cell ther­a­py to PhII af­ter clear­ing ear­ly study

Last year
Cell/Gene Tx

Al­most 40 years af­ter an ad­com­m's warn­ing: FDA and spon­sors with­draw ap­proval for an­a­bol­ic steroid

Last year

Off-the-shelf and on the de­cline: Adicet Bio’s shares halved af­ter PhI look at cell ther­a­py

Last year
Cell/Gene Tx

Af­ter cut­ting back on Vuity last fall, Ab­b­Vie culls a sec­ond-gen pres­by­opia eye drop

Last year
Pharma

Nkar­ta breaks si­lence on CAR-NK ther­a­py for AML af­ter a year, shares tum­ble

Last year
Cell/Gene Tx

Aldeyra says its can­di­date won in chron­ic cough PhII, set­ting stage for bout with Mer­ck, GSK

Last year

Xen­tria and Meitheal ink li­cens­ing deal for rare lung dis­ease treat­ment in North Amer­i­ca

Last year
Deals

FDA ap­proves first of two UCB myas­the­nia gravis drugs, fol­low­ing Alex­ion and ar­genx’s lead

Last year
FDA+

Top drug from Sanofi’s $1.5B Kymab buy­out aces PhI­Ib in eczema

Last year

Lil­ly’s pipeline drug re­ta­tru­tide sets new thresh­old for weight loss at med­ical meet­ing re­veal

Last year

Ser­no­va says five di­a­betes pa­tients have now been tak­en off in­sulin af­ter 'cell pouch' ther­a­py

Last year

J&J touts PhII da­ta in rare blood dis­or­der as it plots a piv­otal study

Last year
Pharma

Look­ing to ex­pand Pyrukynd la­bel, Agios treks to­ward PhI­II in sick­le cell dis­ease

Last year

Ava­lo fails asth­ma PhII with lead can­di­date, shares crater

Last year

Fi­bro­Gen re­ports third PhI­II fail­ure in two months, this time in id­io­path­ic pul­monary fi­bro­sis

Last year
First page Previous page 80818283848586 Next page Last page
A service from the Financial Times